MARK4 and Alzheimer disease: These findings highlight the crucial role of dvCA1Calb1− neurons in the early stage of tau pathology and demonstrate the potential of targeting phosphorylated tau through MARK4 knockdown or DEPTAC administration to counter the vulnerability of dvCA1Calb1− neurons and, consequently, ameliorate episodic memory deficits in AD.